NCT02517515

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 650 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a study to evaluate ABT 450/r/ABT-267 and ABT-333 in treatment-naïve and treatment-experienced Asian adults with subgenotype 1b chronic HCV without cirrhosis.

Conditions

• Hepatitis C Virus (HCV)

Interventions

Type	Name	Description
DRUG	ombitasvir/paritaprevir/ritonavir and dasabuvir	Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
DRUG	Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir	Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir

Timeline

• Start date: 2015-07-01
• Primary completion: 2016-10-01
• Completion: 2017-06-01
• First posted: 2015-08-07
• Last updated: 2017-10-27
• Results posted: 2017-10-27